BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction - Seite 2

“The initiation of the CardiALLO MSC clinical trial for HFrEF is a significant milestone in our efforts to improve patients’ lives through the development of new treatments that target the underpinnings of heart disease,” said Peter Altman, Ph.D., BioCardia’s President and CEO. “We are grateful for the support of study sites, patients and families who are actively engaged with BioCardia in our efforts to explore the potential of BCDA-03 as a novel treatment for ischemic HFrEF. We look forward to continuing this close partnership as we actively enroll additional patients in the CardiALLO MSC Study.   Similar to our autologous CardiAMP cell therapy, which this allogenic cell therapy compliments, there are no requirements for immunosuppression, antiarrhythmic drugs, or open chest surgery.”

This study follows BioCardia’s three previous co-sponsored clinical trials with MSCs in ischemic heart failure: TACHFT¹, POSEIDON² and TRIDENT³. These trials included 93 patients treated with culture expanded MSCs or dedicated controls using the Helix delivery system with no observed treatment emergent serious adverse events. The CardiALLO MSC trial builds on the compelling early signals for benefit demonstrated in these previous trials.     

Anticipated 2023 Q4 Milestones:

• Helix Biotherapeutic Delivery System Update on Licensing / Partnerships
  

References:

1. The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT, NCT00768066),
2. The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (POSEIDON, NCT01087996),
3. The Transendocardial Stem Cell Injection Delivery Effects on Neomyogenesis Study (TRIDENT, NCT 02013674)
   

About BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction. For more information visit: www.BioCardia.com.